Retention, HIV risk, and illicit drug use during treatment
Methadone dose and visit frequency
Bibliographic Data
| ID | 11035681 |
|---|---|
| Authors | Howard M Rhoades (Substance Abuse and Mental Health Services Administration), D Creson, Daniel L Creson (The University of Texas at Austin), Ronith Elk (The University of Texas at Austin), Joy M Schmitz (0000-0002-3561-4614, The University of Texas at Austin), J Schmitz, J Grabowski (0000-0002-4215-4505) |
| Year | 1998 |
| Volume | 88 |
| Issue | 1 |
| Pages | 34-39 |
| Publication date | 1998-01-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | American Journal of Public Health (JOURNAL) |
| Journal identifiers | ISSN: 0090-0036 • E-ISSN: 1541-0048 |
| Publisher | American Public Health Association (PUBLISHER • US) |
| DOI | 10.2105/ajph.88.1.34 |
| PMID | 9584030 |
| OpenAlex | W2094620626 |
| Language | EN |
| Citations received | 17 |
| References cited | 11 |
OBJECTIVES: This study examined two major methadone treatment factors, visit frequency and methadone dose, posited to be important in reducing intravenous drug use and human immunodeficiency virus (HIV) transmission. METHODS: One hundred fifty opiate-dependent subjects randomly assigned to four groups received 50 or 80 mg of methadone and attended a clinic 2 or 5 days per week. RESULTS: Survival analysis indicated higher dropout rates for groups having five vs two visits per week (Chi2[1]=7.76). Higher proportions of opiate-positive results on urine screens were associated with lower methadone doses (F[1,91]=4.74). CONCLUSIONS: Receiving take-home doses early in treatment enhanced treatment retention. The 50-mg dose combined with five visits per week produced the worst outcome. Fewer visits enhanced retention at 50 mg, but opiate use rates were higher at this dose than they were for either 80-mg group. The HIV infection rate at entry was 9%. No subjects seroconverted during the study. Risk behaviors for acquired immunodeficiency syndrome declined over time regardless of group/dose assignment. These results have important implications for modification of regulatory and clinic policy changes
Anesthesia · Drug · Heroin · Human immunodeficiency virus (HIV) · Illicit drug · Methadone · Methadone maintenance · Opiate · Psychiatry · Sida · Substance abuse · Urine · Viral disease · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Immunology · Internal Medicine · Medicine · Substance Abuse Treatment and Outcomes
Beliefs About Methadone in an Inner-City Methadone Clinic
An overview of systematic reviews of the effectiveness of opiate maintenance therapies
Factors predicting drop out from, and retention in, specialist drug treatment services
A Users’ Guide to ‘Juice Bars’ and ‘Liquid Handcuffs’
Premature Discharge from Methadone Treatment
Contingency Contracting and Systematic Desensitization for Heroin Addicts in Methadone Maintenance Programs
Patient Perspectives on Buprenorphine/Naloxone
HIV infection as a predictor of methadone maintenance outcomes in Chinese injection drug users
Adoption of methadone take home policy by U.S. state opioid treatment authorities during Covid-19
Interventions to prevent HIV and Hepatitis C in people who inject drugs
The chronotope of the queue
A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011
Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia
Methadone Death, Dosage and Torsade de Pointes
The Methadone Manifesto
Client Retention in the British Columbia Methadone Program, 1996–1999
Disciplining Addictions
| Citations per year | 0.65 |
|---|---|
| Citation span | 2000 - 2024 (25) |
| Highly cited | No |